Kaneka has been the leading developer of many innovative and cutting edge improvements in the production and quality of coenzyme Q10
Pasadena, TX, (PRWEB) March 24, 2011
Kaneka Nutrients L.P. (KNL) announced today that its parent company Kaneka Corporation (Kaneka) has filed a patent infringement lawsuit on March 22, 2011, in the U.S. District Court for the Central District of California in Los Angeles, Case No. 2:11-cv-02389.
Kaneka’s lawsuit accuses Zhejiang Medicine Co., Ltd. (ZMC), ZMC-USA, LLC, Xiamen Kingdomway Group Company, Pacific Rainbow International Inc., Mitsubishi Gas Chemical Company Inc., Maypro Industries, Inc., and ShenZhou Biology & Technology Co., Ltd. of infringing Kaneka’s U.S. Patent No. 7,910,340 (“the ’340 Patent”) relating to oxidized coenzyme Q10.
ZMC and ZMC-USA filed two declaratory judgment actions, in the U.S. Courts for the Southern District of Texas and the District of Columbia, requesting a declaration of non-infringement and invalidity of the ’340 Patent. Kaneka believes that these actions are premature and without sufficient legal basis, and plans to file motions with the respective courts to dismiss these actions.
Oxidized coenzyme Q10 (Ubiquinone) is also known by its trade name Kaneka Q10™. Kaneka has been the recognized industry leader in coenzyme Q10 for the past 30 years, and is the largest manufacturer of coenzyme Q10 in the world. KNL is the first and only manufacturer of coenzyme Q10 in the United States.
The new lawsuit continues Kaneka’s worldwide enforcement policy for the protection of its intellectual property rights. “Kaneka has been the leading developer of many innovative and cutting edge improvements in the production and quality of coenzyme Q10,” said Mr. Yoshimi Uchida, General Manager of QOL Division at Kaneka. He added: “Kaneka will vigorously defend these rights and will not hesitate to initiate court proceedings to protect its intellectual property.” Mr. Uchida emphasized that “Kaneka’s goal is to protect the results of its research and development and to avoid the unauthorized use of its innovations.”